Recent Finacing
Recent Raise
Myrobalan Therapeutics is a preclinical biotech developing orally bioavailable, brain‑penetrant small‑molecule neurorestorative therapies—GPR17 antagonist, CSF1R and TYK2 inhibitors—targeting remyelination and neuroinflammation in CNS diseases.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
